We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in our Urology. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.

story of the week

Journal Scan / Research · November 30, 2022

Long-Term (5-Year) Outcomes of Stereotactic Ablative Body Radiotherapy in Patients With Primary Renal Cell Carcinoma

The Lancet Oncology

 

Additional Info

Disclosure statements are available on the authors' profiles:

The Lancet Oncology
5-year outcomes after stereotactic ablative body radiotherapy for primary renal cell carcinoma: an individual patient data meta-analysis from IROCK (the International Radiosurgery Consortium of the Kidney)
Lancet Oncol 2022 Nov 15;[EPub Ahead of Print], S Siva, M Ali, RJM Correa, A Muacevic, L Ponsky, RJ Ellis, SS Lo, H Onishi, A Swaminath, M McLaughlin, SC Morgan, FL Cury, BS Teh, A Mahadevan, ID Kaplan, W Chu, W Grubb, R Hannan, M Staehler, A Warner, AV Louie

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Renal Cell Carcinoma Center of Excellence

Visit our Renal Cell Carcinoma Center of Excellence for additional, in-depth coverage.


Further Reading